1. Scrip
  2. >>Business

Junshi Joins China mRNA Mania Through Immorna JV

Latest Partner For In-Demand Venture

 
• By Dexter Jie Yan

After immuno-oncology, mRNA is fast becoming a hot area in China as a flurry of biotechs from I-Mab to Kangtai partner with a little-known developer.

Junshi forms JV with Immorna
Junshi becomes fourth Chinese biopharma firm to collaborate with domestic mRNA specialist Immorna. • Source: Alamy

Shanghai-based immuno-oncology developer Shanghai Junshi Biosciences Co., Ltd. has pledged up to RMB799m ($123m) in a joint venture with Immorna, a domestic messenger RNA technology specialist.

The venture will use mRNA technology provided by Immorna (Hangzhou) Biotechnology Co., Ltd. to develop and commercialize new drugs designed for the global market in multiple fields including cancer, infectious diseases, rare diseases and other disorders, Junshi said

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.